Genes associated with prostate cancer are differentially expressed in african american and european american men

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 5, 2013, Pages 891-897

  Powell, Isaac J ^a   Dyson, Greg ^a   Land, Susan ^a   Ruterbusch, Julie ^a   Bock, Cathryn H ^a   Lenk, Steve ^a   Herawi, Mehsati ^a   Everson, Richard ^b   Giroux, Craig N ^a   Schwartz, Ann G ^a   Bollig Fischer, Aliccia ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKT1 PROTEIN; AROMATASE; BONE MORPHOGENETIC PROTEIN 2; CHEMOKINE RECEPTOR CXCR4; FORMALDEHYDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPID; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE C3; PHOSPHATIDYLINOSITOL 3 KINASE CA; PHOSPHATIDYLINOSITOL 3 KINASE RECEPTOR 1; PHOSPHOLIPASE A2 GROUP II; PHOSPHOLIPASE A2 GROUP IIA; PROTEIN KINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR ERG; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER PATIENT; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; EMBEDDING; EUROPEAN AMERICAN; FORMALIN FIXED PARAFFIN EMBEDDED; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RACE DIFFERENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE SECTION;

AFRICAN AMERICANS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATIC NEOPLASMS;

EID: 84877936647     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-1238     Document Type: Article

References (26)

1. Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from populationbased data. J Natl Cancer Inst 2010;102:1584-98.
2. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 2008;68: 927-36.
3. Whittemore AS, Lele C, Friedman GD, Stamey T, Vogelman JH, Orentreich N. Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst 1995;87: 354-60.
4. Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol 2004;22:439-45.
5. Gokce N, Holbrook M, Duffy SJ, Demissie S, Cupples LA, Biegelsen E, et al. Effects of race and hypertension on flow-mediated and nitroglycerin-mediated dilation of the brachial artery. Hypertension 2001; 38:1349-54.
6. Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004;12: 180-6.
7. Post JM, Beebe-Dimmer JL, Morgenstern H, Neslund-Dudas C, Bock CH, Nock N, et al. The metabolic syndrome and biochemical recurrence following radical prostatectomy. Prostate Cancer 2011;2011: 245642.
8. Prabhat P, Tewari R, Natu SM, Dalela D, Goel A, Tandon P, et al. Is central obesity, hyperinsulinemia and dyslipidemia associated with high-grade prostate cancer? A descriptive cross-sectional study. Indian J Urol 2010;26:502-6.
9. Rose AE, Satagopan JM, Oddoux C, Zhou Q, Xu R, Olshen AB, et al. Copy number and gene expression differences between African American and Caucasian American prostate cancer. J Transl Med 2010; 8:70.
10. Sboner A, Demichelis F, Calza S, Pawitan Y, Setlur SR, Hoshida Y, et al. Molecular sampling of prostate cancer: A dilemma for predicting disease progression. BMC Med Genomics 2010;3:8.
11. Kattar MM, Grignon DJ, Wallis T, Haas GP, Sakr WA, Pontes JE, et al. Clinicopathologic and interphase cytogenetic analysis of papillary (chromophilic) renal cell carcinoma. Mod Pathol 1997;10: 1143-50.
12. Powell IJ, Banerjee M, Sakr W, Grignon D, Wood DP Jr., Novallo M, et al. Should African-American men be tested for prostate carcinoma at an earlier age than white men? Cancer 1999;85: 472-7.
13. Nguyen PL, Ma J, Chavarro JE, Freedman ML, Lis R, Fedele G, et al. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol 2010;28: 3958-64.
14. Tsai CY, Lee TS, Kou YR, Wu YL. Glucosamine inhibits IL-1betamediated IL-8 production in prostate cancer cells by MAPK attenuation. J Cell Biochem 2009;108:489-98.
15. Finley DS, Calvert VS, Inokuchi J, Lau A, Narula N, Petricoin EF, et al. Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol 2009;182:1621-7.
16. Fairfax BP, Vannberg FO, Radhakrishnan J, Hakonarson H, Keating BJ, Hill AV, et al. An integrated expression phenotype mapping approach defines common variants in LEP, ALOX15 and CAPNS1 associated with induction of IL-6. Hum Mol Genet 2010;19: 720-30.
17. Jia L, Choong CS, Ricciardelli C, Kim J, Tilley WD, Coetzee GA. Androgen receptor signaling: Mechanism of interleukin-6 inhibition. Cancer Res 2004;64:2619-26.
18. Yang L, Yeh SD, Xie S, Altuwaijri S, Ni J, Hu YC, et al. Androgen suppresses PML protein expression in prostate cancer CWR22R cells. Biochem Biophys Res Commun 2004;314:69-75.
19. Ha S, Ruoff R, Kahoud N, Franke TF, Logan SK. Androgen receptor levels are upregulated by Akt in prostate cancer. Endocr Relat Cancer 2011;18:245-55.
20. Lee SO, Lou W, Nadiminty N, Lin X, Gao AC. Requirement for NF-(kappa)B in interleukin-4-induced androgen receptor activation in prostate cancer cells. Prostate 2005;64:160-7.
21. Dasgupta S, Srinidhi S, Vishwanatha JK. Oncogenic activation in prostate cancer progression and metastasis: Molecular insights and future challenges. J Carcinog 2012;11:4.
22. Li F, Malik KU. Angiotensin II-induced Akt activation is mediated by metabolites of arachidonic acid generated by CaMKII-stimulated Ca2(?)-dependent phospholipase A2. Am J Physiol Heart Circ Physiol 2005;288:H2306-16.
23. Lai TH, Fong YC, Fu WM, Yang RS, Tang CH. Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins. Prostate 2008;68:1341-53.
24. Dubrovska A, Elliott J, Salamone RJ, Telegeev GD, Stakhovsky AE, Schepotin IB, et al. CXCR4 expression in prostate cancer progenitor cells. PLoS One 2012;7:e31226.
25. Flajollet S, Tian TV, Flourens A, Tomavo N, Villers A, Bonnelye E, et al. Abnormal expression of theERGtranscription factor in prostate cancer cells activates osteopontin. Mol Cancer Res 2011;9:914-24.
26. Rosen P, Pfister D, Young D, Petrovics G, Chen Y, Cullen J, et al. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology 2012;80:749-53.